Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults
Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound NBI-1117570 in healthy adult patients.
This investigational compound is an oral, muscarinic M1/M4 selective dual agonist that could be used in the treatment of neurological and neuropsychiatric conditions. The compound was developed using Sosei Heptares’ structure-based drug design platform.
Eiry W Roberts, MD, chief medical officer at Neurocrine Biosciences, commented: “Initiation of this phase 1 study represents an important step forward for NBI-1117570, a potentially first-in-class, orally active, selective investigational dual M1/M4 agonist. The selectivity profile of NBI-1117570 in targeting M1 and M4 receptors may provide an opportunity to treat symptoms of both psychosis and cognition across a broad range of neurological and neuropsychiatric conditions.”
Matt Barnes, president of Heptares Therapeutics and head of UK R&D, added: “We are delighted that Neurocrine is progressing this unique M1/M4 selective agonist into clinical development to target important unmet medical needs in neurological and neuropsychiatric disorders. NBI-1117570 is the second candidate to advance into clinical trials from the portfolio of selective muscarinic receptor agonists discovered and licensed by Sosei Heptares to Neurocrine in 2021. We look forward to reporting further progress from these and potentially other candidates under this highly productive partnership.”
AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …
Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …